Literature DB >> 23499890

Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition.

Jeffrey T Chang1, Sendurai A Mani.   

Abstract

Multiple cancers contain subpopulations that exhibit characteristics of cancer stem cells (CSCs), the ability to self-renew and seed heterogeneous tumors. Recent evidence suggests two potentially overlapping models for these phenotypes: one where stem cells arise from multipotent progenitor cells, and another where they are created via an epithelial to mesenchymal transition. Unraveling this issue is critical, as it underlies phenomena such as metastasis and therapeutic resistance. Therefore, there is intense interest in understanding these two types of CSSs, how they differ from differentiated cancer cells, the mechanisms that drive their phenotypes, and how that knowledge can be incorporated into therapeutics.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Cellular plasticity; EMT; Epithelial–mesenchymal transition

Mesh:

Year:  2013        PMID: 23499890      PMCID: PMC3762892          DOI: 10.1016/j.canlet.2013.03.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  158 in total

Review 1.  TGFbeta signaling in growth control, cancer, and heritable disorders.

Authors:  J Massagué; S W Blain; R S Lo
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Linking colorectal cancer to Wnt signaling.

Authors:  M Bienz; H Clevers
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

4.  The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells.

Authors:  E Batlle; E Sancho; C Francí; D Domínguez; M Monfar; J Baulida; A García De Herreros
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

5.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion.

Authors:  J Comijn; G Berx; P Vermassen; K Verschueren; L van Grunsven; E Bruyneel; M Mareel; D Huylebroeck; F van Roy
Journal:  Mol Cell       Date:  2001-06       Impact factor: 17.970

6.  Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression.

Authors:  J R Graff; E Gabrielson; H Fujii; S B Baylin; J G Herman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

7.  Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast.

Authors:  S Droufakou; V Deshmane; R Roylance; A Hanby; I Tomlinson; I R Hart
Journal:  Int J Cancer       Date:  2001-05-01       Impact factor: 7.396

Review 8.  TGF-beta signaling in tumor suppression and cancer progression.

Authors:  R Derynck; R J Akhurst; A Balmain
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

9.  Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity.

Authors:  A Eger; A Stockinger; B Schaffhauser; H Beug; R Foisner
Journal:  J Cell Biol       Date:  2000-01-10       Impact factor: 10.539

Review 10.  Regulation of cadherin adhesive activity.

Authors:  B M Gumbiner
Journal:  J Cell Biol       Date:  2000-02-07       Impact factor: 10.539

View more
  14 in total

1.  Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization.

Authors:  Didier Meseure; Kinan Drak Alsibai; Andre Nicolas
Journal:  Cancer Microenviron       Date:  2014-12-19

Review 2.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

3.  Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells.

Authors:  Yao-Min Chen; Yu Liu; Hai-Yan Wei; Ke-Zhen Lv; Peifen Fu
Journal:  Tumour Biol       Date:  2016-02-16

4.  PCBP1 is an important mediator of TGF-β-induced epithelial to mesenchymal transition in gall bladder cancer cell line GBC-SD.

Authors:  Hang-Yu Zhang; Ke-Feng Dou
Journal:  Mol Biol Rep       Date:  2014-06-03       Impact factor: 2.316

Review 5.  Cancer stem cells--the current status of an old concept: literature review and clinical approaches.

Authors:  Lukasz Fulawka; Piotr Donizy; Agnieszka Halon
Journal:  Biol Res       Date:  2014-12-10       Impact factor: 5.612

6.  Differential Roles for DUSP Family Members in Epithelial-to-Mesenchymal Transition and Cancer Stem Cell Regulation in Breast Cancer.

Authors:  Tara Boulding; Fan Wu; Robert McCuaig; Jennifer Dunn; Christopher R Sutton; Kristine Hardy; Wenjuan Tu; Amanda Bullman; Desmond Yip; Jane E Dahlstrom; Sudha Rao
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

7.  Targeting of alpha-v integrins reduces malignancy of bladder carcinoma.

Authors:  Geertje van der Horst; Lieke Bos; Maaike van der Mark; Henry Cheung; Bertrand Heckmann; Philippe Clément-Lacroix; Giocondo Lorenzon; Rob C M Pelger; Rob F M Bevers; Gabri van der Pluijm
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

8.  Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling.

Authors:  Jianguo Wu; Andrei I Ivanov; Paul B Fisher; Zheng Fu
Journal:  Elife       Date:  2016-03-22       Impact factor: 8.140

9.  Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition.

Authors:  Asoka Banno; Daniel A Garcia; Eric D van Baarsel; Patrick J Metz; Kathleen Fisch; Christella E Widjaja; Stephanie H Kim; Justine Lopez; Aaron N Chang; Paul P Geurink; Bogdan I Florea; Hermen S Overkleeft; Huib Ovaa; Jack D Bui; Jing Yang; John T Chang
Journal:  Oncotarget       Date:  2016-04-19

Review 10.  NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?

Authors:  Sten Friberg; Andreas M Nyström
Journal:  J Nanobiotechnology       Date:  2016-03-09       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.